

Supplementary Table 2. Characteristics of kidney transplant recipients by incident post-kidney transplantation Alzheimer disease

Variable	No Alzheimer disease (n = 8,798)	Alzheimer disease (n = 43)	p-value
Age (yr)	52.4 ± 7.4	61.7 ± 6.1	<0.001
40–44	1,469 (16.7)	0 (0)	
45–49	1,847 (21.0)	2 (4.7)	
50–54	2,181 (24.8)	3 (7.0)	
55–59	1,682 (19.1)	12 (27.9)	
60–64	1,081 (12.3)	9 (20.9)	
65–69	429 (4.9)	14 (32.6)	
≥70	109 (1.2)	3 (7.0)	
Male sex	5,334 (60.6)	26 (60.5)	>0.99
Year grading (yr)			0.03
2007–2009	1,943 (22.1)	15 (34.9)	
2010–2012	3,004 (34.1)	17 (39.5)	
2013–2015	3,851 (43.8)	11 (25.6)	
Income			0.15
Medical aid	1,256 (14.3)	3 (7.0)	
Q1	1,272 (14.5)	5 (11.6)	
Q2	1,282 (14.6)	8 (18.6)	
Q3	1,813 (20.6)	5 (11.6)	
Q4	3,175 (36.1)	22 (51.2)	
Charlson comorbidity index			0.01
0	63 (0.7)	1 (2.3)	
1–2	2,618 (29.8)	6 (14.0)	
3–4	2,557 (29.1)	9 (20.9)	
≥5	3,560 (40.5)	27 (62.8)	
Diabetes mellitus	3,757 (42.7)	30 (69.8)	0.001
Hypertension	8,181 (93.0)	42 (97.7)	0.37
Dyslipidemia	4,933 (56.1)	33 (76.7)	0.01
Cardiovascular disease	2,131 (24.2)	18 (41.9)	0.01
Dialysis modality			0.19
Preemptive	2,829 (32.2)	12 (27.9)	
Hemodialysis	3,861 (43.9)	17 (39.5)	
Peritoneal dialysis	1,600 (18.2)	13 (30.2)	
Mixed	508 (5.8)	1 (2.3)	
Dialysis vintage period	3.0 ± 3.4	2.5 ± 2.9	0.29
<3 mo	3,203 (36.4)	12 (27.9)	
3 mo–1 yr	753 (8.6)	5 (11.6)	
1–2 yr	662 (7.5)	7 (16.3)	
2–3 yr	567 (6.4)	7 (16.3)	
3–4 yr	568 (6.5)	2 (4.7)	
4–5 yr	555 (6.3)	2 (4.7)	
>5 yr	2,490 (28.3)	8 (18.6)	
Immunosuppressive treatment			
Desensitization	1,463 (16.6)	9 (20.9)	0.58
Induction			0.39
No use	370 (4.2)	0 (0)	
ATG	820 (9.3)	4 (9.3)	
Basiliximab	7,608 (86.5)	39 (90.7)	
Maintenance CNI			0.46
No use	242 (2.8)	0 (0)	
Tacrolimus	7,231 (82.2)	35 (81.4)	
Cyclosporine	1,325 (15.1)	8 (18.6)	

Data are expressed as mean ± standard deviation or number (%).
ATG, antithymocyte globulin; CNI, calcineurin inhibitor; Q, quartile.